Peptide vaccines incorporate one or more short or long amino acid sequences as tumor
antigens, combined with a vaccine adjuvant. Thus, they fall broadly into the category of …

Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been and is still widely
used as an adjuvant in clinical trials of vaccination with autologous tumor cells, peptides …

Purpose Nineteen patients with high-risk resected stage III and IV melanoma were
immunized with three tumor antigen epitope peptides from gp100, MART-1, and tyrosinase …

Purpose Immunotherapy has a long history with striking but limited success in patients with
melanoma. To date, interleukin-2 and interferon-alfa2b are the only approved …

Survival of melanoma varies widely by stage, from a potentially highly curable disease when
detected in early stages, to a disease with dismal prognosis when it reaches advanced …

The incidence of melanoma continues to increase even as advances in immunotherapy
have led to survival benefits in advanced stages. Vaccines are capable of inducing strong …

Despite the improvement in the outcome of anticancer therapy achieved during the last few
years, several metastatic tumors remain resistant to therapy. This is particularly true for …

Malignant melanoma continues to increase in incidence throughout the developed world.
Surgery remains the cornerstone of curative treatment and the use of adjuvant systemic …

Various kinds of immunotherapy treatment for cancer are either available to the public or are
in the process of clinical trials. Immunotherapy treatments have the potential to treat cancer …

Twenty-four (24) pretreated patients with relapsed high-risk resected The American Joint
Committee on Cancer (AJCC) stage IIA–IV melanoma received adjuvant peptide …